Take the pledge to vote

For a better tommorow#AajSawaroApnaKal
  • I agree to receive emails from News18

  • I promise to vote in this year's elections no matter what the odds are.
  • Please check above checkbox.

    SUBMIT

Thank you for
taking the pledge

Vote responsibly as each vote counts
and makes a diffrence

Disclaimer:

Issued in public interest by HDFC Life. HDFC Life Insurance Company Limited (Formerly HDFC Standard Life Insurance Company Limited) (“HDFC Life”). CIN: L65110MH2000PLC128245, IRDAI Reg. No. 101 . The name/letters "HDFC" in the name/logo of the company belongs to Housing Development Finance Corporation Limited ("HDFC Limited") and is used by HDFC Life under an agreement entered into with HDFC Limited. ARN EU/04/19/13618
LIVE TV DownloadNews18 App
News18 English
News18 » India
1-min read

Biocon Biologics Acquires R&D Facility From Pfizer Healthcare at Ticel Bio Park in Chennai

Biotechnology major Biocon Biotechnology major Biocon has acquired research and development (R&D) capital assets of a 60,000-square feet research facility at Ticel Bio Park in Chennai.

PTI

Updated:September 24, 2019, 11:39 AM IST
facebookTwitterskypewhatsapp
Biocon Biologics Acquires R&D Facility From Pfizer Healthcare at Ticel Bio Park in Chennai
Biotechnology major Biocon Biotechnology major Biocon has acquired research and development (R&D) capital assets of a 60,000-square feet research facility at Ticel Bio Park in Chennai.

New Delhi: Biotechnology major Biocon on Tuesday said its subsidiary has acquired a Chennai-based biological research facility from Pfizer Healthcare for an undisclosed amount.

Biocon Biotechnology major Biocon has acquired research and development (R&D) capital assets of a 60,000-square feet research facility at Ticel Bio Park in Chennai, Biocon said in a statement.

The high-end integrated R&D facility in Chennai will enable Biocon Biologics to expand its R&D capability and accelerate its journey towards meeting its strategic long-term goal of addressing the needs of millions of patients worldwide," Biocon Biologics CEO Christiane Hamacher said.

This investment will allow the company to fast-forward development of its biosimilars from lab to pilot scale, he added. The facility will house an early stage research and innovation centre, including a pilot scale R&D unit equipped with cell line development, drug product formulation laboratories and analytical R&D laboratories.

The facility is expected to be operational in a few months post qualification and will house over 250 scientists. This acquisition provides Biocon Biologics a significant time advantage in comparison to setting up a greenfield R&D project and will accelerate the global development of its biosimilars portfolio, the company said.

At present, the company has one R&D centre at Bengaluru. Biocon Biologics has a product pipeline of 28 molecules, including 11 with Mylan, few with Sandoz and rest on its own. Biocon shares were trading 0.64 per cent higher that their previous close at Rs 226.85 on the BSE.

Get the best of News18 delivered to your inbox - subscribe to News18 Daybreak. Follow News18.com on Twitter, Instagram, Facebook, Telegram, TikTok and on YouTube, and stay in the know with what's happening in the world around you – in real time.

Read full article
Next Story
Next Story

Also Watch

facebookTwitterskypewhatsapp

Live TV

Countdown To Elections Results
To Assembly Elections 2018 Results